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et al., 1997; Salamone et al., 1998; Deuschl et al., 2000; Morrison 
et al., 2008). While the most common form of parkinsonian resting 
tremor in humans is a “pill rolling” tremor of the hands, tremulous 
“up-and-down” movements of the jaw in parkinsonian patients 
have also been well documented (Barbeau, 1986; Selby, 1986; Young, 
1986; Hunker and Abbs, 1990; Adams and Victor, 1993; Ben-Pazi 
et al., 2001; Schneider et al., 2006; Sheffield and Jankovic, 2007; 
Leventoglu and Baysal, 2008; Jankovic, 2009). Oral tremor also is 
induced by long-term administration of DA antagonists, a condi-
tion known as “rabbit syndrome” and defined as “rhythmic jaw 
tremor” (Weiss et al., 1980). This type of tremor is alleviated by 
common antiparkinsonian drugs, but exacerbated by cholinomi-
metic administration (Sovner and Dimascio, 1977; Weiss et al., 
1980; Yassa and Lal, 1986). Thus, it is considered to be a form of 
drug-induced parkinsonian tremor (Sovner and Dimascio, 1977; 
Weiss et al., 1980; Tarsy, 1983).
The neural network thought to underlie parkinsonian tremor 
is complex, consisting of changes to the open and closed loop con-
nections between neocortex, basal ganglia, and thalamus. According 
to current models of basal ganglia function, reductions of the DA 
input from substantia nigra pars compacta (particularly from the 
retrorubral area A8 portion of the SNc in tremor-dominant PD) 
to the striatum leads to an increase in output from the subthalamic 
nucleus (STN), a nucleus consisting of neurons and circuits that are 
Parkinsonian resting tremor
Idiopathic Parkinson’s disease is just one member of a broader fam-
ily of motor disorders known as parkinsonism (Alvarez et al., 2007), 
a group that also includes encephalitic, pugilistic, and drug-induced 
parkinsonism. Regardless of subtype, all forms of parkinsonism 
share in common four core symptoms: bradykinesia, postural insta-
bility, rigidity, and tremor (Hoehn and Yahr, 1967). Tremor, defined 
as “a rhythmic and involuntary oscillation of a body part, caused 
by reciprocal innervations of a muscle, which leads to repetitive, 
stereotyped contractions with regular frequency and amplitude,” is 
sometimes considered to be the cardinal symptom of parkinsonism 
(Deuschl et al., 2000; Mansur et al., 2007). This tremor, present 
predominantly at rest, appears early on in the disease course and 
causes a significant amount of life distress (Mansur et al., 2007). It 
presents in up to 75% of individuals with PD, and has been shown 
to occur in a frequency range of 3–7 Hz, a range distinct from that 
seen in dyskinesias (1–2 Hz), essential tremor (8 Hz), and postural 
tremors (8–12 Hz; Findley et al., 1981; Findley and Capildeo, 1984; 
Marsden, 1984; Elbe and Koller, 1990; Hunker and Abbs, 1990; 
Deuschl et al., 1996, 2000; Spieker et al., 1997).
Usually beginning unilaterally in the distal segments of the 
extremities, parkinsonian tremor frequently spreads bilaterally, 
often affecting both upper and lower limbs, as well as facial mus-
cles, as the disease progresses (Adams and Victor, 1993; Koster 
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doi: 10.3389/fnsys.2011.00049the pharmacology of tremor (e.g., Schrag et al., 2002; Navan et al., 
2003, 2005; Sung et al., 2008; Binder et al., 2009) and there is 
considerable uncertainty about the neurochemical mechanisms 
that underlie the pathophysiology of parkinsonian tremor (Wilms 
et al., 1999; Deuschl et al., 2000, 2001; Bergman and Deuschl, 2002; 
Sung et al., 2008). While parkinsonian tremor seems to result from 
oscillating activity in the central nervous system (and not due to 
reflexes in the periphery; see Hunker and Abbs, 1990 for review), 
it appears to be generated by multiple oscillators, and it is unclear 
where these oscillators are located (though the basal ganglia loops 
are a likely candidate, oscillators in the thalamus have also been 
proposed) or by what mechanism these oscillators produce tremor 
(O’Suilleabhain and Matsumoto, 1998; Deuschl et al., 2000). Given 
the uncertainty surrounding this cardinal symptom of parkinson-
ism, studies employing animal models of parkinsonian resting 
tremor are imperative (Muthuraman et al., 2008). Basic research 
using animal models of drug-induced tremor enables researchers 
to investigate the neurochemical mechanisms that regulate tremor 
and to study the development of oscillatory patterns of activity in 
the brain that are thought to underlie tremorogenesis. Eventually, 
this research could lead to the development of novel treatments.
the tremulous Jaw movement model in rodents: 
develoPment and validation
While a variety of animal models of parkinsonian tremor exist, 
most of these are models of postural or action tremors, and not 
of resting tremor (see Wilms et al., 1999). Although a few models 
of resting tremor have been produced, these have mainly been in 
primates and have involved the destruction of multiple nuclei or 
pathways, a paradigm that is expensive and impractical for most 
preclinical pharmaceutical testing (Wilms et al., 1999). The tremu-
lous jaw movement (TJM) model may provide a resolution for 
many of these difficulties. TJMs, defined as rapid vertical deflections 
of the lower jaw that are not directed at any stimulus, are a rodent 
model of parkinsonian resting tremor (for reviews, see Salamone 
et al., 1998, 2001, 2005; see also Rodriguez Diaz et al., 2001; Cenci 
et al., 2002). TJMs generally occur in phasic bursts of repetitive jaw 
movement activity, with multiple movements within each burst. 
Willner (1990) cautions that animal models should undergo an 
evaluation for their validity using criteria similar to those used in 
the rigorous validation of psychological tests. Thus, a great deal 
of effort has been expended in the analysis of the pharmacologi-
cal, temporal, and anatomical characteristics of the TJM model in 
order to evaluate whether these tremulous movements in rats are 
sufficiently similar to human parkinsonian tremor to allow for their 
validation as an animal model of tremor. TJMs have been shown to 
possess many of the neurochemical, anatomical, and pharmacologi-
cal characteristics of parkinsonism, and thus meet a reasonable set 
of validation criteria for use as an animal model of parkinsonian 
tremor (Salamone et al., 1998; Cenci et al., 2002). Animal mod-
els in psychopharmacology are evaluated for their validity based 
upon a number of criteria (Willner, 1990). These including face 
validity (the phenomenological similarity between the model and 
the disorder, including etiology and symptomatology), construct 
validity (the degree of similarity between the identified variable 
(e.g., tremor), and the behavior being studied in the model), and 
predictive validity (primarily, the positive response to therapeutic 
particularly correlated with tremor (Reck et al., 2009). This, in turn, 
produces an overstimulation of GABAergic neurons in substantia 
nigra pars reticulata (SNr) and globus pallidus internal (GPi), and 
a subsequent inhibition of the ventral lateral and ventral anterior 
nuclei of the thalamus, leading ultimately to the reduced output 
of the sensorimotor cortex and the motor impairments observed 
in parkinsonism. Most recently, hypotheses of parkinsonism have 
focused not just on these changes in firing rates, but also on altera-
tions in firing patterns (see Obeso et al., 2000, 2008; Bevan et al., 
2002; Brown, 2003 for review). Specifically, increases in the activity 
of subthalamic and internal globus pallidus neurons are thought 
to cause these nuclei to enter a regime of rhythmic firing, resulting 
in an excessive synchrony (particularly in the Beta band; Bergman 
et al., 1998; Obeso et al., 2000, 2008; Brown et al., 2001; Levy et al., 
2002). This excessive synchrony may be particularly important for 
the generation and maintenance of parkinsonian tremor.
The neurochemical cascade thought to underlie parkinsonian 
tremor is similarly multifaceted, with multiple neurotransmitters, 
including GABA, serotonin, adenosine, and acetylcholine (ACh), 
interacting with DA in the regulation of basal ganglia motor func-
tions related to parkinsonism (Hornykiewicz, 1972, 1973; DeLong, 
1990; Young and Penney, 1993; McSwain and Forman, 1995; Finn 
et al., 1997b; Hauber et al., 1998; Salamone et al., 1998; Mayorga 
et al., 1999a; Wichmann et al., 2001; Trevitt et al., 2002; Carlson et al., 
2003a,b; Ishiwari et al., 2004; Obeso et al., 2008; Vanover et al., 2008). 
Interestingly, these other neurotransmitters offer additional avenues 
for therapeutic intervention. In addition to DAergic treatments for 
parkinsonism, muscarinic antagonists often are used as antiparkin-
sonian agents, and they have been shown in clinical studies to sup-
press tremor (McEvoy, 1983; Schrag et al., 1999; Milanov, 2001; Koller, 
2002). More recently, antagonists of adenosine A2A receptors have 
been shown to produce antitremor effects in animal models (Correa 
et al., 2004; Salamone et al., 2008a,b) and in human patients with 
Parkinson’s disease (Bara-Jimenez et al., 2003; Pinna, 2009).
The study of parkinsonian tremor has proven to be something 
of an enigma in the field. Although tremor is considered to be 
the most specific marker of parkinsonism, with estimates of 95% 
probability that the presence of classical resting tremor indicates 
idiopathic PD, tremor severity has not been shown to parallel 
disease progression (Deuschl et al., 2000). Additionally, the sys-
tem dynamics of parkinsonian tremor have shown that, despite 
the nearly uniform frequencies associated with tremor-related 
oscillations (i.e., 3–7 Hz; Hunker and Abbs, 1990), these oscilla-
tions occur independently of one another, with electromyographic 
(EMG) activity of tremor in one limb being uncorrelated to the 
EMG activity of another limb exhibiting tremor (O’Suilleabhain 
and Matsumoto, 1998; Hurtado et al., 2000, 2004; Raethjen et al., 
2000, 2009; Ben-Pazi et al., 2001). Even within the tremor circuitry 
itself, tremors have not been shown to be tightly correlated with 
tremor-related neural activity in the nuclei of the basal ganglia 
and thalamus: tremor-related neural activity may wax and wane 
while limb tremor persists; conversely, tremor-related oscillations 
may exist in the neurocircuitry while no limb tremor is apparent 
(Hurtado et al., 2004). These seemingly paradoxical findings have 
led to a variety of questions about the pathophysiology underlying 
tremorogenesis in parkinsonism. Yet despite these lingering ques-
tions, relatively few clinical studies have specifically emphasized 
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occur in the same local frequency range as Parkinsonian 
tremor
Parkinsonian resting tremor in humans is generally reported to 
occur within a peak frequency range of 3–7 Hz (Adams and Victor, 
1993; Staude et al., 1995). This range is distinct from that seen in 
dyskinesias (1–2 Hz), essential tremor (8 Hz), and postural tremors 
(8–12 Hz) (Findley et al., 1981; Findley and Gresty 1981, 1988; 
Findley and Capildeo, 1984; Marsden, 1984; Findley, 1988; Elbe 
and Koller, 1990; Hunker and Abbs, 1990; Deuschl et al., 1996, 
2000; Spieker et al., 1997). Strikingly, the tremulous oral move-
ments that are induced by interference with DA transmission and 
by cholinomimetics have also been found to occur within the 3 to 
7-Hz range, consistent with the frequency of parkinsonian resting 
tremor in humans (See and Chapman, 1991; Salamone and Baskin, 
1996; Finn et al., 1997b; Mayorga et al., 1997; Cousins et al., 1998; 
Salamone et al., 1998; Ishiwari et al., 2005; Collins et al., 2010a; 
Galtieri et al., 2010).
Studies employing slow-motion videotaping methods have 
demonstrated that the majority of TJMs induced either by inter-
ference with striatal dopamine (either through DA depletion 
or antagonism; Salamone and Baskin, 1996; Finn et al., 1997b; 
Ishiwari et al., 2005) or cholinomimetic stimulation (Finn et al., 
1997b; Mayorga et al., 1997; Collins et al., 2011) occur in “bursts” 
with a local frequency range of 3–7 Hz (based on an analysis of 
the inter-movement time, whereby local frequency was equal to 
the inverse of the inter-movement time). EMG recording methods 
also have been used to characterize the local frequency of TJMs. 
Cousins et al. (1998) found that the lateral temporalis muscle is the 
drugs). As described below, the TJM model of parkinsonism is 
one of the few models of experimental tremor that meets these 
validation criteria.
validation of the tremulous Jaw movement model: tJms are 
induced by the same neurochemical and Pharmacological 
conditions that lead to Parkinsonism in humans
Tremulous jaw movements are induced by a number of condi-
tions that parallel the neurochemistry of idiopathic and drug-
induced parkinsonism. For example, several DAergic conditions 
that are associated with parkinsonism in humans have been 
shown to induce TJMs (Table 1). Depletions of striatal dopamine 
by the neurotoxic agent 6-OHDA (Jicha and Salamone, 1991; 
Finn et al., 1997b; Rodriguez-Diaz et al., 2001) or acute admin-
istration of reserpine (Baskin and Salamone, 1993; Steinpreis 
and Salamone, 1993; Salamone and Baskin, 1996; Salamone 
et al., 2008b) have been shown to induce TJM activity in rats. 
Several studies have demonstrated that TJMs are also induced by 
acute or sub-chronic administration of “typical” antipsychotic 
drugs that act as DA antagonists (Glassman and Glassman, 1980; 
Rupniak et al., 1985, 1986; Jicha and Salamone, 1991; Steinpreis 
and Salamone, 1993; Steinpreis et al., 1993; Egan et al., 1996; 
Trevitt et al., 1998; Wisniecki et al., 2003; Ishiwari et al., 2005; 
Betz et al., 2007, 2009; Collins et al., 2010a). In contrast, “atypi-
cal” antipsychotic drugs, such as clozapine, olanzapine, and 
quetiapine, which are less likely to induce motor side effects 
in humans, do not induce TJMs (Trevitt et al., 1998, 1999; Betz 
et al., 2005, 2009).
Cholinomimetic drugs acting on central muscarinic recep-
tors, which can produce or exacerbate parkinsonian symp-
toms in humans (Duvoisin, 1967; Aquilonius, 1980; Ott and 
Lannon, 1992; Kao et al., 1993; Song et al., 2008), also produce 
robust bursts of TJM activity in rats (Rupniak et al., 1983, 1985; 
Salamone et al., 1986, 2005; Table 1). Muscarinic agonists, such 
as pilocarpine, have been repeatedly demonstrated to induce 
TJMs (Rupniak et al., 1983, 1985; Salamone et al., 1986, 1990; 
Stewart et al., 1987, 1988; Baskin et al., 1994; Finn et al., 1997a,b; 
Collins et al., 2010a). Similar findings have been reported with the 
administration of various anticholinesterases, including phys-
ostigmine and tacrine (Kelley et al., 1989; Mayorga et al., 1997; 
Simola et al., 2004; Tronci et al., 2007; Kasture et al., 2009; Pinna 
et al., 2010). Most recently, galantamine, a “new generation” 
anticholinesterase, was demonstrated to induce TJMs (Collins 
et al., 2011; Figure 1). This is consistent with data from clinical 
patient populations, which suggest that the “new generation” 
anticholinesterases donepezil, rivastigmine, and galantamine also 
induce tremor (Bourke and Drukenbrod, 1998; Shea et al., 1998; 
Arai, 2000; Aarsland et al., 2003; Gurevich et al., 2006; McCain 
et al., 2007; Litvinenko et al., 2008; Song et al., 2008). Donepezil, 
for example, has been reported to induce jaw tremor as a side 
effect (Song et al., 2008). Given the increasing numbers of people 
receiving anticholinesterases for the treatment of Alzheimer’s 
disease, this is particularly concerning, and suggests that a new 
population of people may be at risk for developing drug-induced 
tremor. These observations indicate that research on the patho-
genesis of tremor needs to include anticholinesterase-induced 
tremor as well as DAergic conditions.
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Figure 1 | effects of different iP doses of the anticholinesterase 
galantamine on tremulous jaw movements (Collins et al., 2011).  
Mean (± SEM) number of jaw movements (per 5 min) in rats (n = 8) treated with 
either saline vehicle (Veh) or galantamine. Using a within-groups design, all rats 
received all drug treatments in a randomly varied order (one treatment per 
week). Rats were observed in three 5-min periods 10–25 min after injection. 
Repeated measures ANOVA revealed that galantamine produced a significant 
increase in tremulous jaw movement activity [F(4,28) = 25.8; p < 0.001]. 
*Significant difference from vehicle control (p < 0.05).
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Administration of l-DOPA, currently the gold standard for the 
treatment of parkinsonian motor impairment, led to a significant 
reduction of TJMs (Cousins and Salamone, 1996; Cousins et al., 
1997). Similarly, several DA agonists, including apomorphine, per-
golide, bromocriptine, ropinirole and CY 208-243, have been shown 
to reduce TJMs (Baskin and Salamone, 1993; Cousins et al., 1997; 
Salamone et al., 2005). The potency of DAergic drugs for suppressing 
TJMs is highly correlated with the clinical potency of these drugs for 
reducing parkinsonian tremor in humans (Salamone et al., 2005). 
For example, the weak partial D1 agonist SKF 38393, which is not 
antiparkinsonian in humans or primates (Braun et al., 1987; Boyce 
et al., 1990; Close et al., 1990), did not decrease cholinomimetic-
induced jaw movements (Cousins et al., 1997). Conversely, the full 
DA D1 receptor agonists SKF 82958 and dihydrexidine, which have 
been shown to have antiparkinsonian actions in MPTP-treated pri-
mates (Taylor et al., 1991; Akai et al., 1995a,b; Gnanalingham et al., 
1995), are capable of producing a robust suppression of cholinomi-
metic-induced TJMs (Mayorga et al., 1999a).
jaw closing muscle most strongly correlated with tacrine-induced 
TJMs in rats; examination of 1 s raw EMG traces demonstrated that 
the local frequency of these TJMs was in the 3 to 7-Hz frequency 
(Cousins et al., 1998). Furthermore, this study indicated that the 
variability in the jaw movement frequency distribution obtained 
was comparable to the variability in tremor frequencies shown 
by parkinsonian patients (see Staude et al., 1995). A more recent 
study demonstrated that the frequency range of TJMs induced by 
the muscarinic agonist pilocarpine were in the 3 to 7-Hz frequency 
range after both a high (4.0 mg/kg) and low (0.5 mg/kg) dose 
(Collins et al., 2010a).
Currently, improvements in the frequency characterization of 
TJMs are being conducted using time series analysis of EMG data. 
Since the physiological events underlying tremor can be considered 
as a continuously varying waveform, the use of these continuous 
time series techniques (as opposed to discrete stochastic point 
process techniques) is appropriate for the analysis of the EMG 
data obtained from rats displaying TJMs (Halliday et al., 1995). 
More specifically, because tremor has been described as a second 
order linear stochastic process, spectral analysis techniques based 
on the Fourier transform can be used (Timmer et al., 1998a,b). 
The employment of these techniques provides for a systematic, 
quantitative temporal analysis of EMG data recorded during 
drug-induced TJMs. A recent study employed these techniques to 
perform a frequency analysis of the jaw movements induced by 
both DA antagonism and cholinomimetic administration (Collins 
et al., 2010c). Rats were implanted with tungsten wire electrodes 
bilaterally in the lateral temporalis muscle. Following a sufficient 
recovery period, rats received either an acute injection of the mus-
carinic agonist pilocarpine, the anticholinesterase galanthamine, 
or a sub-chronic injection of the DA D2 antagonist pimozide. Rats 
were then connected to a Cheetah 16 Neuralynx recording system 
(Neuralynx, Bozeman, MT, USA) via a mutliwire cable and record-
ings of EMG activity during TJM observation were performed. 
Representative traces were examined using the Neuraview program 
(Neuralynx, Bozeman, MT, USA) to identify appropriate epochs of 
tremor and non-tremor activity and then imported into Matlab 7.4 
(Mathworks Inc., Natick, MA, USA). A spectrum of each epoch was 
then calculated using the multi-taper spectral estimation method. 
Spectral analysis revealed that, during periods of tremor activ-
ity, a distinct peak was consistently present between 4 and 7 Hz. 
This was true for tremor activity induced by both DA antagonism 
and cholinomimetic administration. Conversely, during periods 
of quiescence (i.e., when no tremor activity was occurring in the 
jaw), no distinct peak was present in the spectral analysis. Example 
traces and spectral analyses are presented in Figure 2. These results 
with time series analysis demonstrate that drug-induced TJMs are 
accompanied by EMG activity that is occurring in the parkinsonian 
tremor frequency range, and serve to provide further validation of 
the TJM model of parkinsonian resting tremor.
validation of the tremulous Jaw movement model: tJms are 
reversed by well characterized and Putative 
antiParkinsonian drugs
In addition to being produced by many of the same neurochemi-
cal conditions that induce parkinsonism in humans, TJMs in rats 
also can also be reduced by both clinically utilized and   putative 
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Figure 2 | electromyography (eMg) from temporalis muscle in rats 
injected with 0.5 mg/kg of the muscarinic agonist pilocarpine (iP). Raw 
EMG traces and spectral analyses of the EMG data during periods with 
tremulous jaw movements (top) and without tremulous jaw movements 
(bottom). During bouts of jaw movement activity, rats show bursts of muscle 
activity (raw EMG trace, bottom left); spectral analyses revealed a peak in the 5 
to 6-Hz frequency range for this trace (arrow).
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correlated with the presence of tremor in human parkinsonian 
patients (Bernheimer et al., 1973). Overall, the VLS is considered 
to be a critical striatal subregion at which DA, ACh, and adenosine 
receptor mechanisms interact to regulate TJMs (Salamone et al., 
1998, 2008b; see VLS section in Figure 3).
Depletions of DA in the VLS by local injections of 6-OHDA were 
shown to induce TJMs, while injections in other striatal regions 
were ineffective (Jicha and Salamone, 1991; Finn et al., 1997a). 
A similar pattern has been reported using manipulations of the cho-
linergic system (Kelley et al., 1989; Salamone et al., 1990; Kikuchi 
de Beltran et al., 1992). Microdialysis methods demonstrated that 
increases in extracellular levels of ACh in VLS were correlated 
with the jaw movements induced by tacrine and physostigmine 
(Cousins et al., 1999). Cholinomimetic-induced TJMs were sup-
pressed by local injections of muscarinic antagonists into the VLS 
but not into the medial striatum (Kelley et al., 1989; Salamone 
et al., 1990; Kikuchi de Beltran et al., 1992; Mayorga et al., 1997). 
Hemicholinium, which reduces ACh synthesis by blocking high 
affinity choline uptake, suppressed tacrine-induced jaw movements 
when injected into the VLS, but not into overlying cortex (Cousins 
et al., 1999). The suppression of pilocarpine-induced jaw move-
ments that was produced by the DA D1 agonist SKF 82958 was 
reversed by injections of the D1 antagonist SCH 23390 into VLS, but 
not overlying cortex (Mayorga et al., 1999a). In addition, injections 
of the c-AMP analog 8-bromo-c-AMP into the VLS suppressed 
pilocarpine-induced jaw movements, while injections into cortex 
were ineffective (Mayorga et al., 1999b).
Most recently, it has been hypothesized that the VLS is the 
neostriatal subregion within which adenosine A2A antagonists can 
suppress TJM activity. Recent studies demonstrated that injec-
tions of the adenosine A2A antagonist MSX-3 directly into the 
VLS suppressed the TJMs induced by the DA antagonist pimozide 
Antiparkinsonian anticholinergics, such as the muscarinic 
antagonists benztropine, scopolamine, and atropine, also reliably 
suppress TJM activity (Rupniak et al., 1983; Salamone et al., 1986, 
1990; Steinpreis et al., 1993; Salamone and Baskin, 1996; Cousins 
et al., 1997; Mayorga et al., 1997; Betz et al., 2007, 2009; Table 2). 
Taken together with studies showing that cholinomimetics can 
induce TJMs, these findings reinforce the idea that the striatal 
DA and ACh systems interact in a complex way to regulate motor 
function and dysfunction (Aquilonius, 1980; Zigmond et al., 1987; 
Olianas et al., 1996; Salamone et al., 1998, 2001; Olianas and Onali, 
1999; Calabresi et al., 2000, 2006; Pisani et al., 2003, 2007; Zhou 
et al., 2003; Morris et al., 2004; Cragg, 2006; Threlfell et al., 2010). 
The striatum contains large aspiny cholinergic neurons, and is rich 
in muscarinic receptors, with M1 and M4 subtypes being the pre-
dominant postsynaptic receptors (Hersch et al., 1994; Santiago and 
Potter, 2001). The M4 subtype of muscarinic receptor in particular 
has been implicated in the regulation of TJM activity (Mayorga 
et al., 1999c; Salamone et al., 2001; Betz et al., 2007, 2009).
Most recently, the ability of adenosine A2A antagonists to reverse 
TJMs has been extensively studied (Table 2). Adenosine A2A receptors 
are highly expressed in neostriatum, and A2A antagonists exert motor 
effects in rodents and primates that are consistent with antiparkin-
sonian actions (Ferré et al., 1997, 2004; Rosin et al., 1998; Chen et al., 
2001; Morelli and Pinna, 2001; Morelli et al., 2007; Salamone et al., 
2008b; Collins et al., 2010a,b). Human clinical reports have indicated 
that the adenosine A2A antagonists istradefylline (KW 6002), prelad-
enant (SCH 420814), ST-1535, and BIIB014 significantly improve 
motor deficits, reduce OFF time, and increase ON time in parkin-
sonian patients, suggesting that members of this drug class may be 
efficacious as antiparkinsonian agents (Hauser et al., 2003, 2008; 
Jenner, 2005; LeWitt et al., 2008; Stacy et al., 2008; Gillespie et al., 
2009; Pinna, 2009; Factor et al., 2010; Fernandez et al., 2010; Mizuno 
et al., 2010; Salamone, 2010; Knebel et al., 2011). The adenosine A2A 
antagonists KF 17837, istradefylline, SCH 58261, ST 1535, ANR94, 
AA47070, MSX-3, and MSX-4 have all been shown to significantly 
reverse the TJMs induced by DA depletion, DA antagonism, and 
cholinomimetic administration (Correa et al., 2004; Simola et al., 
2004; Tronci et al., 2007; Salamone et al., 2008a; Betz et al., 2009; 
Collins et al., 2010a; Pinna et al., 2010; Collins et al., 2011; Collins-
Praino et al., 2011b). The ability of TJMs to be reversed by several 
classes of commonly used as well as experimental antiparkinsonian 
drugs provides support for the predictive validity of the TJM model 
as a rodent model of parkinsonian tremor.
validation of the tremulous Jaw movement model: 
anatomical characteristics of the tJms in rats are similar to 
those of human Parkinsonian tremor
Multiple studies have demonstrated that TJMs induced by interfer-
ence with DA transmission and by cholinomimetic administration 
are dependent upon striatal mechanisms, particularly upon the ven-
trolateral striatum (VLS). The VLS, thought to be a rodent homolog 
of the primate ventral putamen, is somatotopically  organized (Pisa, 
1988; Jicha and Salamone, 1991; Salamone et al., 1993a,b) and 
receives input from sensory and motor cortices related to head, 
orofacial, and forepaw areas (McGeorge and Faull, 1989; Salamone 
et al., 1998). Since the VLS is considered to be the homolog of the 
primate ventral putamen, it is interesting to note that the putamen 
VLS VLS
VentrolateralN eostriatum (VLS)
Figure 3 | Drawing of coronal section from rat brain, modified from 
Pellegrino et al. (1979) to show location of the ventrolateral neostriatum 
(VLS), which is a critical striatal subregion at which DA, ACh, and 
adenosine receptor mechanisms interact to regulate tremulous jaw 
movements (see text for references).
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tions. Moreover, it provides avenues for the development of novel 
treatments for tremor.
In view of the continued uncertainty about the pathophysi-
ology of parkinsonian tremor (Deuschl et al., 2000; Sung et al., 
2008), it is important to identify the physiological conditions that 
are correlated with the generation of tremulous movements in 
animal models. As described above, pharmacological evidence 
links the VLS subregion of the neostriatum to the production 
of TJMs. In a recent preliminary study, increased tremor-related 
oscillatory activity in local field potential (LFP) signals was 
observed within the VLS subregion of the neostriatum during the 
occurrence of   pilocarpine-induced TJMs (Collins et al., 2010c). 
During tremor activity, there was a sharp increase in LFP power 
in the VLS in the 5 to 8-Hz band (Figure 4). This increase in 
power was noticeably absent in VLS when tremor activity was 
not occurring. This is consistent with findings from the spectral 
analyses of EMG traces recorded from the temporalis muscle 
during tremor and non-tremor epochs (see above). Furthermore, 
during periods of tremor activity, there was a broad increase in 
beta band (15–30 Hz) activity (Figure 4). This increase in beta 
band power was not present during periods without TJM activ-
ity. These findings are consistent with studies obtained from 
parkinsonian patients. Both single-unit and LFP recordings in 
patients with Parkinson’s disease have shown evidence of tremor-
related frequencies (∼4–8 Hz) and increased “beta” (∼8–30 Hz) 
frequency activity in basal ganglia structures, typically globus 
pallidus, and STN (Hutchison et al., 1997; Weinberger et al., 
2006; see also Hutchison et al., 2004 or Hammond et al., 2007 
for reviews). Additionally, increases at both ∼6 Hz (tremor fre-
quency) and ∼20 Hz (beta frequency) can be observed in LFP 
signals in globus pallidus and STN of Parkinson’s disease patients 
off l-DOPA, while after l-DOPA treatment is reinstated, both the 
tremor and beta frequency LFPs diminish (Brown et al., 2001). 
The relationship between a specific neurophysiological phenom-
enon (e.g., altered output in specific structures and changes in 
the frequency of output) and particular Parkinsonian symptoms 
is unclear, although some evidence suggests that the low fre-
quency increase at 4–8 Hz is related to tremor, while the increase 
in “beta” (15–30 Hz) interferes with the initiation and mainte-
nance of movements (Levy et al., 2002; see however Weinberger 
et al., 2006). It has been proposed that the focal (spatial-limited) 
occurrence of gamma (∼40–80 Hz) is associated with movement 
initiation (Courtenmance et al., 2003; Masimore et al., 2005) and 
that changes in striatal neurochemistry that lead to parkinson-
ism transform basal ganglia circuits from participating in focal 
(spatially limited) gamma ensembles toward more global beta 
oscillations (e.g., Pessiglione et al., 2005). In light of this, the 
findings of increases in VLS LFP power at 4–8 Hz and in the beta 
band during TJMs may provide important information about the 
physiological mechanisms underlying tremorogenesis.
Tremulous jaw movements have also been examined in relation 
to hippocampal theta and epileptiform activity. Doses of the cho-
linergic agonist pilocarpine can induce increases in theta (6–10 Hz) 
during awake-immobility in the rat, but there was no obvious 
temporal relationship between theta and the presence/absence of 
TJMs (Collins et al., 2010c; Figure 5). In addition, although very 
(Salamone et al., 2008a). In addition, the adenosine A2A antagonist 
istradefylline reversed pimozide-induced c-Fos expression in the 
VLS at a dose that also suppressed pimozide-induced TJMs (Betz 
et al., 2009).
tremulous Jaw movements are not a model of 
tardive dyskinesia
Since oral movements in rats have been observed to result from 
chronic administration of DA antagonists, it could be suggested that 
TJMs represent an animal model of tardive dyskinesia (Ellison et al., 
1987; Ellison and See, 1989; Creed et al., 2010). However, several 
lines of evidence conflict with this view. First, the fact that a tremor 
is orofacial does not make it a model of tardive dyskinesia, per se. As 
reviewed above, parkinsonian tremors can include up-and-down 
movements of the jaw (Barbeau, 1986; Hunker and Abbs, 1990), 
and “rabbit syndrome” is a drug-induced parkinsonian tremor that 
is characterized by chewing-like movements (Sovner and Dimascio, 
1977; Weiss et al., 1980; Tarsy, 1983). Differences between rodents 
and humans in the relative prevalence of hand versus jaw tremor 
may simply be due to species differences in motor system anatomy 
and physiology (i.e., the relative proportion of the motor system 
dedicated to orofacial versus limb control in rodents and humans; 
Salamone et al., 1998).
By definition, tardive dyskinesia is produced by chronic admin-
istration of DA antagonists. In contrast, TJMs in rats can be pro-
duced by acute or sub-chronic administration of DA antagonists 
(Glassman and Glassman, 1980; Rupniak et al., 1985, 1986; Jicha 
and Salamone, 1991; Steinpreis and Salamone, 1993; Steinpreis 
et al., 1993; Egan et al., 1996; Ishiwari et al., 2005; Salamone et al., 
2008a; Collins et al., 2010a; Galtieri et al., 2010) or by acute DA 
depletion with reserpine (Baskin and Salamone, 1993; Steinpreis 
and Salamone, 1993; Salamone et al., 2008b). Furthermore, while 
muscarinic ACh antagonists reduce both parkinsonian symptoms 
in humans and TJMs in rats (Betz et al., 2007; Collins et al., 2011), 
they worsen tardive dyskinesia (Fahn et al., 1974; Burnett et al., 
1980; Noring et al., 1984). Similarly, while l-DOPA reduces TJMs 
(Cousins et al., 1997), it is well known to induce dyskinesias. 
Finally, as described earlier, the jaw movements induced by DA 
depletion or cholinomimetics have frequency  characteristics that 
are quite different from tardive dyskinesia. While TJMs show 
maximal activity in the 3 to 7-Hz frequency range (See and 
Chapman, 1991; Salamone and Baskin, 1996; Finn et al., 1997b; 
Mayorga et al., 1997; Cousins et al., 1998; Salamone et al., 1998; 
Ishiwari et al., 2005; Collins et al., 2010a; Galtieri et al., 2010), 
tardive dyskinesia is typically in the range of 1–2 Hz (Alpert 
et al., 1976; Wirshing et al., 1989a,b).
the utility of the tremulous Jaw movement model 
for assessing novel treatment strategies for 
tremor: recent develoPments
As described above, basal ganglia regulation of motor function 
involves interactions between a wide array of transmitters and 
neuromodulators, including DA, ACh, adenosine, 5-HT, GLU, 
and GABA, as well as circuits that interconnect striatal and non-
striatal regions. The complexity of these interactions provides 
a daunting challenge to the investigator, but it also provides a 
framework for understanding how a symptom such as tremor 
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eMg (Left: bottom trace in each pair) with and without rhythmic eMg activity 
(temporalis muscle) in behaving-rat following 0.5 mg pilocarpine. Traces were 
recording 10–15 min following treatment. Power spectral density (right) of 2-s traces 
indicate prominent increase in power in 5–8 Hz band as well as a broad increase in 
beta band “15–30” Hz activity (see arrows). Note increased frequency and regularity 
of ∼5 Hz signal in traces with rhythmic EMG activity as compared to slower and less 
regular LFP traces in absence of rhythmic EMG activity.
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Figure 5 | electromyographic (eMg) activity indicates the presence of 
jaw movement activity (upper left trace). Concurrently recorded 
hippocampal LFP indicates the absence of hippocampal theta (middle left). In 
another trace, EMG indicates a jaw movement burst (upper right trace) 
occurring in the presence of hippocampal theta (middle right). The two 
phenomena occur independently of each other and are not correlated. 
Additionally, no epileptiform activity is present during the occurrence of either 
jaw movement burst at the dose of 0.5 mg/kg pilocarpine. Epileptiform activity 
only becomes apparent at a much higher dose of pilocarpine (i.e., 50 mg/kg 
pilocarpine, data not shown).
high doses of pilocarpine such as 50.0–100 mg/kg IP can produce 
epileptiform activity, no epileptiform activity is seen under phar-
macological conditions that produce TJMs (data not shown). In 
conjunction with the earlier findings presented, these recent data 
provide further evidence that TJMs are being induced via actions 
within the VLS itself and not being driven by other factors, such 
as hippocampal theta or epileptiform activity.
Tremulous jaw movements have become a useful model for 
experimental assessment of diverse tremorogenic and tremoro-
lytic conditions. As reviewed above, adenosine A2A antagonists 
can suppress TJMs; consistent with this observation, we recently 
found that systemic administration of non-sedative doses of the 
A2A agonist CGS 21680 can induce TJMs (Figure 6). Moreover, 
TJMs have been shown to be attenuated by several serotonergic 
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clear consensus on the mechanism of action of DBS has yet to 
be reached, and several competing hypotheses have been put 
forward. Animal models of tremor could be useful for investi-
gating potential mechanisms of action of DBS. In a recent study 
by Collins-Praino et al. (2011a), TJMs were induced by a DA 
D1 antagonist (SCH 39166), a DA D2 antagonist (pimozide), a 
muscarinic agonist (pilocarpine), and an anticholinesterase (gal-
antamine). Unilateral high frequency stimulation (130 Hz) of the 
STN, but not of a striatal control site, was shown to be effective 
at reversing the TJMs induced by all four pharmacological agents 
(Figure 7). Stimulation at lower  frequencies or intensities failed to 
decrease TJMs compared to baseline “OFF” epochs, indicating that 
this response is not only dependent upon the brain area stimu-
lated but also upon the frequency and intensity parameters used. 
When the adenosine A2A antagonist MSX-3 was co-administered 
with high frequency stimulation of the STN, both the frequency 
and intensity parameters necessary to produce a suppression of 
galantamine-induced TJMs were drastically reduced (Figure 7). 
These results serve to provide a further validation of the TJM 
model, and also may have critical significance for the selection of 
parameters used during deep brain stimulation in parkinsonian 
patients undergoing this procedure for the treatment of medically 
refractory tremor. Based on the results of this study, it is possi-
ble that the prescription of an adenosine A2A antagonist to these 
patients may result in a significant reduction in the frequency 
and/or intensity parameters needed for therapeutic efficacy and, 
thereby, a near doubling of the therapeutic window for these 
parkinsonian patients.
CGS 21680 and Tremulous Jaw Movements
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Figure 6 | effect of the adenosine A2A agonist CgS 21680 on the 
induction of tremulous jaw movements. One group of rats was used; all 
animals received IP injections of the following doses: saline vehicle, 0.1 mg/
kg, 0.2 mg/kg, and 0.4 mg/kg (n = 8). Using a within-groups design, all rats 
received all drug treatments in a randomly varied order (one treatment per 
week). Injections were given 5 min before the animals were placed in a TJM 
observation chamber. All animals were allowed to habituate in the chamber for 
10 min, and were subsequently observed for tremulous jaw movements for 
15 min. Data are shown as mean (±SEM) number of individual jaw 
movements (per 15 min observation period). Systemic injections of CGS 
21680 induced tremulous jaw movements overall [F(3,21) = 9.15, p < 0.001]. 
Planned comparisons indicated that there were significant differences 
between vehicle and 0.1 mg/kg CGS 21680 and 0.2 mg/kg (*p < 0.05). At the 
0.4-mg/kg dose of CGS 21680, rats showed profound sedation, and were 
either drowsy or asleep during the observation period. (Data are from the 
Pharm D. honors thesis of Dr. K. L. Rychalsky, University of Connecticut).
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Figure 7 | effect of subthalamic nucleus deep brain stimulation on the 
tremulous jaw movements induced by 3.0 mg/kg of the 
anticholinesterase galantamine (iP; data are from Collins-Praino et al., 
2011a). All rats were implanted with unilateral subthalamic nucleus stimulating 
electrodes. After injection of galantamine, rats had alternating 5-min periods of 
stimulation off, followed by stimulation on; stimulation frequency was varied 
across the session. This curve shows the frequency-dependence of the effect 
of deep brain stimulation on tremulous jaw movements; there was an overall 
suppressive effect of brain stimulation on jaw movement activity 
[F(3,50) = 4.6, p < 0.01]. *p = 0.05; ***p < 0.001.
drugs, including the serotonin 5-HT2 family antagonist mianserin 
(Carlson et al., 2003b), the 5-HT2A receptor inverse agonist, ACP-
103 (Vanover et al., 2008), and the 5-HT(1A) agonists 8-OH-DPAT, 
buspirone, and F-97013-GD (Zazpe et al., 2006). The TJM model 
also has been incorporated into methods used to discriminate 
between the effects of typical antipsychotics and later-generation 
compounds such as clozapine, olanzapine, and quetiapine (Chesler 
and Salamone, 1996; Trevitt et al., 1998, 1999; Betz et al., 2005). 
Tacrine-induced TJMs also were shown to be suppressed by the 
T-type calcium channel blocker zonisamide (Miwa et al., 2008, 
2009, 2011), which has anticonvulsant and tremorolytic effects 
in humans. Furthermore, stimulation of GABA transmission in 
SNr, either by local injection the GABAA agonist muscimol (Finn 
et al., 1997a) or by nigral transplantation of engineered GABA-
producing cells (Carlson et al., 2003a) reduced cholinomimetic-
induced TJMs.
In recent years, high frequency stimulation of the STN has 
become a standard treatment of tremor used by neurosurgeons 
(Ashkan et al., 2004). In MPTP-treated primates, high frequency 
stimulation of the STN has been shown to improve rigidity and 
motor scores (Benazzouz et al., 1993, 1996; Ashkan et al., 2004). In 
1993, the first bilateral STN electrodes were implanted in human 
patients, and high frequency STN stimulation improved rigid-
ity, tremor, akinesia, postural/gait instabilities, independence, 
and quality of life, as well as reducing drug-induced dyskinesias 
(Benabid et al., 1994; Limousin et al., 1995, 1998; Ashkan et al., 
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Table 2 | Antiparkinsonian drugs that reverse tremulous jaw movements.
DA Precursors (l-DOPA) Cousins and Salamone (1996), Cousins et al. (1997)
DA Agonists Baskin and Salamone (1993), Cousins et al. (1997), Mayorga et al. (1999a), Salamone et al. (2005)
Amantadine Cousins et al. (1997)
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conclusion
In conclusion, the TJM model shares many of the pharma-
cological, temporal, and anatomical characteristics of human 
parkinsonian tremor. Thus, it can be viewed as meeting a rea-
sonable set of validation criteria as a rodent model of parkin-
sonian resting tremor. The validation of this model represents 
a significant advance forward in the scientific study of parkin-
sonian resting tremor, which still has a great deal of uncertainty 
surrounding its pathophysiology. The TJM model allows for 
basic research into the neurochemical mechanisms that regulate 
tremor, and the development of   oscillatory patterns of activ-
ity in the brain that are thought to underlie tremorogenesis. 
Eventually, this research may lead to the development of novel 
treatments for tremor.
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